Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05087550 · ClinicalTrials.gov registry record

Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation

A clinical trial, sponsored by Methodist Health System.

Completed
Registry status
186
Enrollment target

NCT05087550: Completed study, sponsored by Methodist Health System.

NCT05087550 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 186 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05087550 has completed, sponsored by Methodist Health System.

COMPLETED
Registry status
186 participants
Enrollment target

Study Summary

Organ procurement organizations (OPO) have increased organ recovery efficiency and yield and have also reduced organ acquisition charges. The new liver allocation policy came into effect in February 2020 and aims to increase access to organs for waitlist candidates with the greatest severity of illness. The urgent change was driven by the perception that patients were dying because of arbitrary boundaries and inequitable access. Critics of the new policy have highlighted the potential cost implications particularly at an OPO level. A study of five OPOs throughout the United States highlighted an increase in costs ranging from 43% - 206% despite the same volume of livers transplanted. The main reason for the cost appears to lie in organ handling and transport. This mirrors the findings of Puri and colleagues who acknowledged changes to lung transplantation at Barnes Jewish Hospital in the pre- and post-policy eras and reported a substantial decline in local donors. The new lung system has also resulted in a higher organ discard rate and ultimately higher costs. Such data has generated meaningful discussions regarding optimizing organ allocation polices, however, data from individual transplant centers is lacking in the literature. Changes at a transplant center level relating to recipient costs are likely impacted by the new policy, which could be related to patient travel, accommodation, work up etc.

Interventions

  • PROCEDURE Liver Transplantation

Trial Details

FieldValue
Enrollment Target 186 participants
Start Date 2021-10-13
Est. Completion 2023-08-09
Methodist Health System

125 total trials

What the finished NCT05087550 record still lists

NCT05087550 is an observational study that tracks outcomes without assigning an intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which Liver Transplantation is the first listed.

NCT05087550 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05087550 about?

NCT05087550 is a clinical study titled "Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation". Organ procurement organizations (OPO) have increased organ recovery efficiency and yield and have also reduced organ acquisition charges. The new liver allocation policy came into effect in February 2020 and aims to increase access to organs for waitlist candidates with the greatest severity of illn...

What is the current status of trial NCT05087550?

This trial is currently completed. The enrollment target is 186 participants. The study started on 2021-10-13. Estimated completion is 2023-08-09.

What interventions are being tested in trial NCT05087550?

The interventions under investigation include: Liver Transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT05087550?

This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03567889 · 186 participants · Phase 3

    Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

  • NCT05281471 · 186 participants · Phase 3

    Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

  • NCT05405595 · 186 participants · Phase 1

    ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

  • NCT05762107 · 186 participants · Phase 2

    A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05087550, the US trial registry maintained by the National Library of Medicine. NCT05087550 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.